Assessment of safety and effectiveness of desoximetasone emollient cream 0.25% in comparison to mometasone cream 0.1% in Indian patients with eczema

Kaushik Lahiri; Shymanta Barua; B. V. Ramesh Babu; Sushil Tahiliani; Kiran Godse; Ketan R. Kulkarni

doi:10.18203/2320-6012.ijrms20220519

Authors

Kaushik Lahiri Department of Dermatology, Apollo Multispeciality Hospital, Kolkata, West Bengal, India
Shymanta Barua Department of Dermatology, Assam Medical College, Dibrugarh, Assam, India
B. V. Ramesh Babu Citizen Skin Clinic, Malleshwaram, Bangalore, Karnataka, India
Sushil Tahiliani Dr. Sushil Tahiliani Skin and Cosmetology centre, Mumbai, Maharashtra, India
Kiran Godse Department of Dermatology, D. Y. Patil Hospital and School of Medicine, Navi Mumbai, Maharashtra, India
Ketan R. Kulkarni Deputy General Manager, Medical Services Emcure Pharmaceuticals Ltd., Pune, Maharashtra, India

DOI:

https://doi.org/10.18203/2320-6012.ijrms20220519

Keywords:

Desoximetasone emollient cream 0.25%, Eczema, Mometasone cream 0.1%, Pruritus

Abstract

Background: Topical corticosteroids have become indispensable in the treatment of eczema. The current study was conducted to assess the safety and effectiveness of Desoximetasone emollient cream 0.25% (DESO) compared to Mometasone cream 0.1% (MOM) in patients with eczema.

Methods: This was a prospective, observational, open label, multicentre post marketing study at real-life scenario. Newly diagnosed, treatment naïve patients with clinical diagnosis of eczema were enrolled. All patients received either DESO or MOM for 3 weeks. Primary end point was proportion of patients developing adverse events. Secondary endpoints comprised of change in visual analog scale for perception of improvement in intensity of pruritus at day 14 and day 21 from baseline, change in eczema area and severity index (EASI) score at day 0 and day 21.

Results: 45 patients in DESO group and 43 patients in MOM group completed study. DESO and MOM were well tolerated. Severity of pruritus was significantly reduced in 54.59% patients in DESO group compared to 45.60% patients in MOM group on day 14 (p=0.023). Severity of pruritus was reduced in 69.16% patients in DESO group as compared to 66.97 % patients in MOM group on day 21 (p=NS). There was a statistically significant reduction (p<0.001) in EASI score at day 21 and as compared to baseline within the study groups, but without any difference between the groups.

Conclusions: Desoximetasone 0.25% emollient cream was well tolerated in the treatment of eczema with earlier reduction in pruritus as compared to Mometasone furoate 1% cream.

Metrics

Metrics Loading ...

References

Jerajani HR, Kumar AS, Kuruvila M, Nataraja HV, Philip M, Pratap D et al. Efficacy and safety of topical halometasone in eczematous dermatoses in Indian population: An open label, noncomparative study. Indian J Dermatol. 2011;56:652-6.

Williams D.M Clinical Pharmacology of Corticosteroids. Respir Care. 2018 ;63(6):655-70.

Spada F, Barnes TM, Greive KA Comparative safety and efficacy of topical mometasone furoate with other topical corticosteroids Australas J Dermatol. 2018;59(3):e168-74

Heel RC, Brogden RN, TM. Speight, Avery G.S. Desoxymethasone: A Review of its Pharmacological Properties and Therapeutic Efficacy in the Treatment of Dermatoses Drugs. 1978;16:302-21.

Katz M, Gans EH. Topical corticosteroids, structure-activity and the glucocorticoid receptor: discovery and development- a process of “planned serendipity”. J Pharm Sci. 2008;97:293647.

Baeck M, Chemelle JA, Rasse M. C16-methyl corticosteroids are far less allergenic than the non-methylated molecules. Contact Dermatitis. 2011;64:305-12.

Ference J.D. Last. A R Choosing Topical Corticosteroids Am Fam Physician. 2009;79(2):135-40.

Prakash A, Benfield P. Topical mometasone. A review of its pharmacological properties and therapeutic use in the treatment of dermatological disorders. Drugs. 1998;55(1):145-63.

Rajka G, Avrach W, Gartner L, Overgaard-Petersen H. Mometasone furoate 0.1% fatty cream once daily versus betamethasone valerate 0.1% cream twice daily in the treatment of patients with atopic and allergic contact dermatitis. 2020;12:4-8.

Hanifin JM, Thurston M, Omoto M, Cherill R, Tofte SJ, Graeber M. The eczema area and severity index (EASI): assessment of reliability in atopic dermatitis. EASI Evaluator Group. Exp Dermatol. 2001;10(1):11-8.

Mehta AB, Nadkarni NJ, Patil SP, Godse KV, Gautam M, Agarwal S. Topical corticosteroids in dermatology. Indian J Dermatol Venereol Leprol. 2016;7:12-4.

Forster JF, Abrams B. Desoximetasone In: Maibach HI, Surber C (eds): Topical Corticosteroids. 1992;388-402.

Spada F, Barnes TM, Greive KA. Comparative safety and efficacy of topical mometasone furoate with other topical corticosteroids Australas J Dermatol. 2018;59(3):e168-e174.

Mitra H.P, Banerjee H.P. Desoximetasone: A new topical corticosteroid. Clinical Evaluation Indian J Dermatol. 1974;20(1):7-15.

Ashton RE, Catterall M, Morley N, Fairris G, Josephs DN. A double-blind comparison of 0.25% and 0.05% desoxymetasone, 0.1% betamethasone valerate and 1% hydrocortisone cream in the treatment of eczema. The Journal of International Medical Research. 1987;I5:160-6.